DRMA
Dermata Therapeutics Inc
NASDAQ: DRMA · HEALTHCARE · BIOTECHNOLOGY
$1.37
+8.73% today
Updated 2026-04-30
Market cap
$4.99M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-8.16
Dividend yield
—
52W range
$1 – $10
Volume
1.8M
Dermata Therapeutics Inc (DRMA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — |
| Cost of revenue | $1355.00 | $322.00 | — | — | — | — | — |
| Gross profit | $-1355.00 | $-322.00 | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $2.62M | $1.61M | $3.46M | $5.65M | $4.07M | $8.20M | $2.93B |
| SG&A | $1.85M | $1.56M | $4.40M | $4.02M | $3.97M | $4.31M | $4.84M |
| Operating income | $-4.47M | $-3.17M | $-7.86M | $-9.67M | $-8.04M | $-12.51M | $-7.77M |
| Operating margin | — | — | — | — | — | — | — |
| EBITDA | $-4.47M | $-3.04M | $-7.84M | $-9.67M | $247216.00 | $-12.29M | $-7.77M |
| EBITDA margin | — | — | — | — | — | — | — |
| EBIT | $-4.47M | $-3.04M | $-7.86M | $-9.67M | $-7.79M | $-24.80M | — |
| Interest expense | $250748.00 | $197269.00 | $45613.00 | $63573.00 | — | — | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-4.72M | $-3.24M | $-7.95M | $-9.61M | $-7.79M | $-12.29M | $-7.56M |
| Net income growth (YoY) | — | +31.4% | -145.6% | -20.9% | +18.9% | -57.6% | +38.5% |
| Profit margin | — | — | — | — | — | — | — |